Señales en vivo de 1681.HK | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 23:59):

Stats
Volumen de hoy	667 000
Volumen promedio	786 395
Capitalización de mercado	4.97B
EPS	HKD0 ( 2024-03-28 )
Próxima fecha de ganancias	( HKD0 ) 2024-05-31
Last Dividend	HKD0.300 ( 2023-06-08 )
Next Dividend	HKD0 ( N/A )
P/E	5.87
ATR14	HKD0.0120 (0.19%)

Volumen Correlación

Largo: -0.16 (neutral)

Corto: -0.25 (neutral)

Signal:(47.058) Neutral

Consun Pharmaceutical Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Consun Pharmaceutical Correlación - Moneda/Commodity

0.50
( neutral )

0.56
( weak )

0.00
( neutral )

0.41
( neutral )

-0.65
( moderate negative )

Consun Pharmaceutical Finanzas

Annual	2023
Ingresos:	HKD2.59B
Beneficio Bruto:	HKD1.92B (74.19 %)
EPS:	HKD0.990

FY	2023
Ingresos:	HKD2.59B
Beneficio Bruto:	HKD1.92B (74.19 %)
EPS:	HKD0.990

FY	2022
Ingresos:	HKD2.34B
Beneficio Bruto:	HKD1.76B (75.35 %)
EPS:	HKD0.860

FY	2021
Ingresos:	HKD2.04B
Beneficio Bruto:	HKD1.53B (74.70 %)
EPS:	HKD0.740

Financial Reports:

No articles found.

Consun Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.300 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Consun Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.45 - good (84.50%) | Divividend Growth Potential Score: 7.06 - Increase likely (41.30%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.0480	2014-09-25
Last Dividend	HKD0.300	2023-06-08
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	19	--
Total Paid Out	HKD2.25	--
Avg. Dividend % Per Year	0.00%	--
Score	3.52	--
Div. Sustainability Score	8.45
Div.Growth Potential Score	7.06
Div. Directional Score	7.76	--

Next Divdend (Est)
(2024-06-24)

HKD0.334 Estimate 3.45 %

Dividend Stability

0.28 Very Poor

Dividend Score

3.52

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8270.HK	No Dividend Player	2023-06-30	Sporadic	0.00%
2016.HK	Ex Dividend Junior	2023-05-17	Annually	0.00%
1084.HK	Ex Dividend Junior	2023-06-06	Semi-Annually	0.00%
0151.HK	Ex Dividend Knight	2023-08-24	Semi-Annually	0.00%
3718.HK	Ex Dividend Junior	2023-09-11	Semi-Annually	0.00%
1658.HK	Ex Dividend Junior	2023-07-05	Annually	0.00%
0696.HK	Ex Dividend Junior	2023-06-20	Annually	0.00%
2218.HK	Ex Dividend Junior	2023-06-02	Annually	0.00%
1223.HK	Ex Dividend Junior	2023-06-27	Sporadic	0.00%
0289.HK	Ex Dividend Knight	2023-10-05	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.303	1.500	3.94	5.91	[0 - 0.5]
returnOnAssetsTTM	0.142	1.200	5.25	6.30	[0 - 0.3]
returnOnEquityTTM	0.227	1.500	8.59	10.00	[0.1 - 1]
payoutRatioTTM	0.416	-1.000	5.84	-5.84	[0 - 1]
currentRatioTTM	2.86	0.800	0.692	0.554	[1 - 3]
quickRatioTTM	2.57	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.838	1.500	0.898	1.347	[0.2 - 2]
debtRatioTTM	0.0929	-1.500	8.45	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	1.018	2.00	9.66	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.953	2.00	9.52	10.00	[0 - 20]
debtEquityRatioTTM	0.141	-1.500	9.44	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.742	1.000	0.968	0.968	[0.2 - 0.8]
operatingProfitMarginTTM	0.319	1.000	5.62	5.62	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.601	1.000	2.22	2.22	[0.2 - 2]
assetTurnoverTTM	0.470	0.800	-0.198	-0.159	[0.5 - 2]
Total Score				8.45

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	5.65	1.000	9.53	0	[1 - 100]
returnOnEquityTTM	0.227	2.50	9.10	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.953	2.00	9.68	10.00	[0 - 30]
dividendYielPercentageTTM	8.17	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.018	2.00	9.66	10.00	[0 - 30]
payoutRatioTTM	0.416	1.500	5.84	-5.84	[0 - 1]
pegRatioTTM	1.224	1.500	5.17	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.316	1.000	4.60	0	[0.1 - 0.5]
Total Score				7.06

Consun Pharmaceutical

Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.